Published in N Engl J Med on September 20, 2001
Mechanisms of Diabetic Kidney Disease in American Indians | NCT01878045
Standards of medical care in diabetes--2013. Diabetes Care (2013) 24.85
Standards of medical care in diabetes--2010. Diabetes Care (2010) 24.28
Standards of medical care in diabetes--2011. Diabetes Care (2011) 21.94
Standards of medical care in diabetes--2012. Diabetes Care (2012) 20.66
Standards of medical care in diabetes--2009. Diabetes Care (2009) 15.78
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart (2005) 9.79
Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol (2010) 9.28
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med (2011) 7.42
Age and association of kidney measures with mortality and end-stage renal disease. JAMA (2012) 7.20
Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med (2009) 6.75
Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA (2012) 6.26
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int (2011) 5.25
Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA (2011) 4.70
Effect of a long-term behavioural weight loss intervention on nephropathy in overweight or obese adults with type 2 diabetes: a secondary analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol (2014) 4.30
Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function. Clin J Am Soc Nephrol (2009) 4.16
Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest (2006) 3.41
Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol (2009) 3.30
Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort. Arch Intern Med (2011) 3.20
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients. Eur Heart J (2012) 3.19
Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol (2010) 3.13
Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol (2011) 3.13
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial. Eur Heart J (2010) 2.68
Failure of ICD-9-CM codes to identify patients with comorbid chronic kidney disease in diabetes. Health Serv Res (2006) 2.61
Liver angiotensinogen is the primary source of renal angiotensin II. J Am Soc Nephrol (2012) 2.58
Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ (2005) 2.57
Guidelines for the management of chronic kidney disease. CMAJ (2008) 2.54
Longitudinal progression trajectory of GFR among patients with CKD. Am J Kidney Dis (2012) 2.51
Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol (2008) 2.48
Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord (2010) 2.47
Cell biology and pathology of podocytes. Annu Rev Physiol (2011) 2.42
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Avosentan for overt diabetic nephropathy. J Am Soc Nephrol (2010) 2.32
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol (2005) 2.25
Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials. Nat Rev Drug Discov (2009) 2.24
Inhibition of diabetic nephropathy by a decoy peptide corresponding to the "handle" region for nonproteolytic activation of prorenin. J Clin Invest (2004) 2.24
Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol (2010) 2.22
Diabetic kidney disease: a clinical update from Kidney Disease: Improving Global Outcomes. Kidney Int (2014) 2.22
Population based screening for chronic kidney disease: cost effectiveness study. BMJ (2010) 2.19
Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy. Nephrol Dial Transplant (2009) 2.17
Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med (2014) 2.17
Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis (2014) 2.16
Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol (2009) 2.12
Targeting effective blood pressure control with angiotensin receptor blockers. Int J Clin Pract (2006) 2.10
Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol (2011) 2.07
Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A (2008) 2.06
Suppression of microRNA-29 expression by TGF-β1 promotes collagen expression and renal fibrosis. J Am Soc Nephrol (2011) 2.06
Aldosterone antagonists for preventing the progression of chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol (2009) 2.04
Pirfenidone for diabetic nephropathy. J Am Soc Nephrol (2011) 2.04
2009 Canadian Hypertension Education Program recommendations: an annual update. Can Fam Physician (2009) 2.03
AT1A angiotensin receptors in the renal proximal tubule regulate blood pressure. Cell Metab (2011) 2.03
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
A role for angiotensin II type 1 receptors on bone marrow-derived cells in the pathogenesis of angiotensin II-dependent hypertension. Hypertension (2009) 1.94
Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. J Am Soc Nephrol (2008) 1.93
Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int (2013) 1.93
Rate of ESRD exceeds mortality among African Americans with hypertensive nephrosclerosis. J Am Soc Nephrol (2010) 1.92
Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J Clin Invest (2006) 1.92
Access to health care among status Aboriginal people with chronic kidney disease. CMAJ (2008) 1.91
Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol (2013) 1.91
CKD in Hispanics: Baseline characteristics from the CRIC (Chronic Renal Insufficiency Cohort) and Hispanic-CRIC Studies. Am J Kidney Dis (2011) 1.88
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
T lymphocytes mediate hypertension and kidney damage in Dahl salt-sensitive rats. Am J Physiol Regul Integr Comp Physiol (2010) 1.84
Serum bicarbonate levels and the progression of kidney disease: a cohort study. Am J Kidney Dis (2009) 1.84
(Pro)renin receptor contributes to diabetic nephropathy by enhancing renal inflammation. Clin Exp Pharmacol Physiol (2009) 1.83
The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med (2008) 1.83
Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol (2009) 1.82
Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys Ther (2008) 1.81
Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol (2012) 1.80
Molecular mechanisms of diabetic kidney disease. J Clin Invest (2014) 1.80
Reno-protective effects of renin-angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis. Diabetologia (2011) 1.80
A novel role for type 1 angiotensin receptors on T lymphocytes to limit target organ damage in hypertension. Circ Res (2012) 1.79
Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care (2014) 1.79
Human recombinant ACE2 reduces the progression of diabetic nephropathy. Diabetes (2009) 1.78
Lymphocyte responses exacerbate angiotensin II-dependent hypertension. Am J Physiol Regul Integr Comp Physiol (2010) 1.76
Increased urinary excretion of angiotensinogen is associated with risk of chronic kidney disease. Nephrol Dial Transplant (2012) 1.75
Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol (2009) 1.72
25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol (2009) 1.71
Glomerular angiotensinogen is induced in mesangial cells in diabetic rats via reactive oxygen species--ERK/JNK pathways. Hypertens Res (2010) 1.71
Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. Am J Physiol Renal Physiol (2008) 1.71
Oxidative stress in diabetic nephropathy. Curr Med Chem (2010) 1.70
Interpreting treatment effects from clinical trials in the context of real-world risk information: end-stage renal disease prevention in older adults. JAMA Intern Med (2014) 1.68
Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol (2009) 1.68
Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev (2010) 1.66
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nat Rev Nephrol (2010) 1.65
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Histopathology of diabetic nephropathy. Semin Nephrol (2007) 1.60
Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens (2010) 1.60
Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation (2012) 1.59
The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int (2012) 1.58
The prevention of cardiovascular disease in cancer survivors. Tex Heart Inst J (2012) 1.57
Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol (2007) 1.55
Gq signaling causes glomerular injury by activating TRPC6. J Clin Invest (2015) 1.54
Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res (1997) 665.31
A computer program for aligning a cDNA sequence with a genomic DNA sequence. Genome Res (1998) 22.69
PipMaker--a web server for aligning two genomic DNA sequences. Genome Res (2000) 17.46
Sox9 is required for cartilage formation. Nat Genet (1999) 7.89
Comparison of DNA sequences with protein sequences. Genomics (1997) 7.76
Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med (2013) 7.51
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med (2001) 6.22
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med (1996) 5.17
Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet (1999) 4.81
AHA Dietary Guidelines: revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation (2000) 4.80
Roles of PLC-beta2 and -beta3 and PI3Kgamma in chemoattractant-mediated signal transduction. Science (2000) 4.61
Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ (1991) 4.46
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (1999) 4.38
Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization. Proc Natl Acad Sci U S A (2001) 4.13
The transcription factors L-Sox5 and Sox6 are essential for cartilage formation. Dev Cell (2001) 4.11
Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet (1995) 4.06
Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst (2001) 3.88
The pathogenesis and diagnosis of foot-and-mouth disease. J Comp Pathol (2003) 3.83
Comparative sequence analysis of a gene-rich cluster at human chromosome 12p13 and its syntenic region in mouse chromosome 6. Genome Res (1998) 3.80
Cryopyrin and pyrin activate caspase-1, but not NF-kappaB, via ASC oligomerization. Cell Death Differ (2006) 3.77
Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mol Cell Biol (1994) 3.66
Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila. Cell (1997) 3.58
Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr (1999) 3.45
Health services: an Italian market. Lancet (1996) 3.43
Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature (2001) 3.42
Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma. J Infect Dis (2000) 3.20
Progression, remission, regression of chronic renal diseases. Lancet (2001) 3.17
Haemolytic-uraemic syndrome: deficiency of plasma factor(s) regulating prostacyclin activity? Lancet (1978) 3.15
Source-zone characterization of a chlorinated-solvent contaminated Superfund site in Tucson, AZ. J Contam Hydrol (2006) 3.10
A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling. Mol Cell Biol (2000) 3.04
Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet (1983) 3.01
Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care (2000) 2.97
The actinomycete Thermobispora bispora contains two distinct types of transcriptionally active 16S rRNA genes. J Bacteriol (1997) 2.96
Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Intern Med (1989) 2.94
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation (2000) 2.90
The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int (1999) 2.87
Modulating the profit motive to meet needs of the less-developed world. Lancet (2001) 2.86
A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int (2006) 2.85
Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol (2000) 2.81
Early detection of patients at risk of developing diabetic nephropathy. A longitudinal study of urinary albumin excretion. Acta Endocrinol (Copenh) (1982) 2.75
Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med (2000) 2.74
Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R. J Biol Chem (2000) 2.73
Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate. J Am Soc Nephrol (1995) 2.73
Distinct types of rRNA operons exist in the genome of the actinomycete Thermomonospora chromogena and evidence for horizontal transfer of an entire rRNA operon. J Bacteriol (1999) 2.72
A simple method of estimating progression of chronic renal failure. Lancet (1976) 2.72
Kinesin family in murine central nervous system. J Cell Biol (1992) 2.70
Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med (1993) 2.70
Ribosomal protein S7 as a novel modulator of p53-MDM2 interaction: binding to MDM2, stabilization of p53 protein, and activation of p53 function. Oncogene (2007) 2.68
beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc Natl Acad Sci U S A (1999) 2.66
The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol (2001) 2.56
Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J Mass Spectrom (1997) 2.54
A method for estimating nitrogen intake of patients with chronic renal failure. Kidney Int (1985) 2.52
Wnt-1 signaling inhibits apoptosis by activating beta-catenin/T cell factor-mediated transcription. J Cell Biol (2001) 2.52
Clinical manifestations and diagnosis of acute pyrethroid poisoning. Arch Toxicol (1989) 2.50
CA 125: the past and the future. Int J Biol Markers (1999) 2.50
Strategies for making more organs available for transplantation. N Engl J Med (2000) 2.48
Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant (2013) 2.45
Xa21D encodes a receptor-like molecule with a leucine-rich repeat domain that determines race-specific recognition and is subject to adaptive evolution. Plant Cell (1998) 2.43
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int (2001) 2.43
The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. J Clin Invest (1996) 2.39
Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis (1999) 2.38
Superfibronectin is a functionally distinct form of fibronectin. Nature (1994) 2.38
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Functional recovery in parkinsonian monkeys treated with GDNF. Nature (1996) 2.35
Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. Diabetologia (2010) 2.35
Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) (1987) 2.35
Copy number variations of chromosome 16p13.1 region associated with schizophrenia. Mol Psychiatry (2009) 2.29
Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia (2011) 2.28
Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr Opin Struct Biol (1999) 2.25
Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages. J Virol (2001) 2.24
Factor H family proteins: on complement, microbes and human diseases. Biochem Soc Trans (2002) 2.23
New structural picture of the Ge2Sb2Te5 phase-change alloy. Phys Rev Lett (2011) 2.21
Mechanisms of edema formation in myxedema--increased protein extravasation and relatively slow lymphatic drainage. N Engl J Med (1979) 2.21
Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest (2001) 2.20
Inhibition of TGF-beta expression: a novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney Int (2007) 2.19
Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: a global perspective. Kidney Int (2006) 2.18
Taste genes associated with dental caries. J Dent Res (2010) 2.17
The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrol Dial Transplant (1998) 2.16
Diabetes and hypertension. Australian Diabetes Society position statement. Med J Aust (1995) 2.14
Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases. Nat Commun (2013) 2.10
Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother (1984) 2.09
Muscle wasting in insulinopenic rats results from activation of the ATP-dependent, ubiquitin-proteasome proteolytic pathway by a mechanism including gene transcription. J Clin Invest (1996) 2.07
Intrastriatal transplantation of bone marrow nonhematopoietic cells improves functional recovery after stroke in adult mice. J Cereb Blood Flow Metab (2000) 2.06
Database of non-canonical base pairs found in known RNA structures. Nucleic Acids Res (2000) 2.06
ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int (2006) 2.05
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics (1999) 2.01